Alzheimer Disease, Neurodegenerative Diseases, Magnetic Resonance Imaging, Memory Impairment
Conditions
Brief summary
Semantic AD
Interventions
DEVICE7T MRI
Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.
DEVICEEEG
Resting-state EEG
BIOLOGICALBlood samples
Blood samples taken for analysis of central blood biomarkers.
BIOLOGICALStool samples
Stool samples collected to identify distinct gut-microbiota compositions between the groups.
DIAGNOSTIC_TESTNeuropsychologic test (MoCA)
Map cognition with clinically well-established neuropsychology test
Sponsors
Norwegian University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Confirmed diagnosis based on current ICD criteria for AD or MCI . * \>55years. * Norwegian native speaker * Lives at home and not in a health institution
Exclusion criteria
* Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2). * Presence of brain tumors. * History of traumatic brain injury. * History of cranial surgery. * Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG). * Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS. 7T MRI contraindications: * Large tattoos close to the head region, permanent makeup or unremoveable piercings * Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred) * Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Understand which individual differences are observed among patients with Alzheimer's disease (AD). | From enrollment to end of follow-up at 1 year. | This outcome will characterize individual variability among patients diagnosed with Alzheimer's disease based on clinical symptoms, cognitive assessments, neuroimaging findings (7T MRI), electrophysiological data (EEG), and biological samples (blood and stool). The goal is to identify patterns or subtypes that may reflect distinct disease mechanisms or progression profiles. |
| Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls. | From project enrollment to end of follow-up at 1 year. | Assess differences between dementia patients and cognitively healthy controls using multimodal data, including 7T MRI for brain structure, EEG, blood biomarkers, and gut microbiome profiles from stool samples. The aim is to identify biological and neurological markers associated with dementia-related changes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Understand which individuals with mild cognitive impairment (MCI) go on to develop Alzheimer's disease (AD). | From enrollment to the end of follow-up time at 1 year. | Identify early clinical, neuroimaging, and biological markers associated with progression from MCI to AD. This research question aims to improve early diagnosis and risk stratification in individuals with MCI. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Compare brain changes in patients with Alzheimer's disease (AD) to those with other types of dementia. | From project encrollment to end of follow-up at 1 year. | This outcome will investigate brain changes in patients with Alzheimer's disease compared to those with other dementia types using the different modalities included in the project. |
Countries
Norway
Contacts
Primary ContactAxel Sandvig Professor, MD & PhD
Backup ContactVaranann Varathalingam
Outcome results
None listed